Acute Heart Failure (AHF) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Acute Heart Failure (AHF) Market Outlook

Thelansis’s “Acute Heart Failure (AHF) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Heart Failure treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Heart Failure (AHF) Overview

Acute heart failure (AHF) is the sudden onset or worsening of symptoms and signs associated with heart failure (HF). This critical condition typically requires hospitalization, focusing on the immediate management of fluid overload and compromised hemodynamics. It encompasses individuals experiencing typical HF symptoms and signs for the first time (de novo AHF) and those with exacerbated symptoms of their existing cardiomyopathy (acute decompensated heart failure). Heart failure (HF) is a clinical syndrome characterized by symptoms, including breathlessness, difficulty breathing while lying down, lower limb swelling, and signs such as elevated jugular vein pressure and lung congestion. These manifestations result from structural and functional abnormalities in the heart, leading to reduced cardiac output and increased pressures within the heart. More than 50% of patients in high-income regions and Eastern and Central European areas, acute heart failure admissions are primarily linked to ischemic heart disease. Globally, hypertension consistently contributes to the occurrence of heart failure. The most common HF symptoms include exertional or resting breathlessness, discomfort when lying flat (orthopnea), fatigue, and reduced exercise capacity. These symptoms are often accompanied by clinical signs such as limb swelling, distended jugular veins, a third heart sound called the "S3 gallop," and pulmonary rales. The European Society of Cardiology (ESC) classified heart failure patients into six groups based on their clinical presentations:

1. Acute decompensated congestive heart failure involves worsening chronic heart failure, characterized by a gradual onset of peripheral edema and significant dyspnea.
2. AHF with hypertension: This is marked by a rapid increase in systolic blood pressure, pulmonary congestion, tachycardia, preserved left ventricular ejection fraction (LVEF), and relatively low mortality.
3. AHF with pulmonary edema: This presents with sudden or gradual severe respiratory distress, widespread lung rales, tachypnea, orthopnea, and arterial oxygen saturation (SaO2) below 90%.
4. Cardiogenic shock: This is a highly fatal syndrome characterized by gradual or rapid organ and tissue hypoperfusion, reduced urine output, and systolic blood pressure below 90 mm Hg.
5. AHF complicating acute coronary syndrome (ACS): This results from increased left ventricular diastolic filling pressure or decreased cardiac output due to myocardial ischemia or infarction.
6. Isolated right-sided AHF: This is characterized by rapid or gradual edema onset, jugular vein distention, hepatomegaly, clear lungs, low blood pressure, reduced left ventricular filling pressure, and decreased cardiac output.

The first-line treatment for acute heart failure is loop diuretics. These drugs include furosemide, bumetanide, and torsemide.

• The prevalence of heart failure is estimated to be 6 million individuals, approximately 1.8% of the US population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: